Sex differences in the impact of CYP2C19 polymorphisms and low-grade inflammation on coronary microvascular disorder
Tomonori Akasaka, Hisao Ogawa(Kumamoto University Hospital), Junji Saruwatari(Kumamoto University), Kentaro Oniki(Kumamoto University), Kenji Sakamoto(Kumamoto University), Daisuke Sueta(Mie University), Ayami Kajiwara(Kumamoto University), Eiichiro Yamamoto(Sapporo Medical University), Seiji Hokimoto(Kumamoto University), Sunao Kojima(Kumamoto University), Koichi Kaikita(Kumamoto University), Megumi Yamamuro(IRYO Sosei University), Noriaki Tabata(Kumamoto University), Yasuhiro Ogata(Japanese Red Cross Kumamoto Hospital), Kazuko Nakagawa(Kumamoto University), Kazunori Morita(Kumamoto University), Kenichi Tsujita(Kumamoto University)
American Journal of Physiology-Heart and Circulatory Physiology
March 19, 2016
Cited by 25
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|755